Biotech // Therapeutics ER Comp
Biotech feels like the one niche in ER that functions differently from virtually any other coverage, so curious what compensation looks like at all levels (is it similar to IB?).
Trending Content - Equity Research Forum
Career Resources
Based on the most helpful WSO content, compensation in Biotech/Therapeutics Equity Research (ER) can vary significantly depending on the level of experience, but it generally does not match the levels seen in Investment Banking (IB). Here's a breakdown of IB compensation for comparison:
While Biotech ER compensation is competitive, it typically trails IB, especially at the higher levels. However, Biotech ER offers unique opportunities, such as deeper specialization in a niche field and potentially better work-life balance compared to IB.
Sources: Work/Life Balance: Equity Research vs. Investment Banking - (A Definitive Guide, Part 1), Exits for biotech/biopharma/life sciences IB, Request for a preclinical biotech pharma model, Divergence in the Drug Businesses: Pharmaceuticals and Biotechnology, JPMorgan ER vs Wells Fargo Investment Banking
The compensation system in the biotechnology (Biotech) sector is truly unique, but it differs fundamentally from that of investment banking. While banking focuses on short-term cash bonuses from closing deals, the biotechnology sector is tied to long-term research phases and FDA drug approvals, so the main driver of wealth here is equity (Equity/Options).
bump
Similique autem deleniti in sed. Vel aut optio cumque. Corrupti pariatur tenetur qui sunt consequuntur corrupti ut alias. Mollitia delectus qui quia architecto sint quaerat dolores quaerat. Est natus ratione suscipit eum. Eum est quia quas doloribus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...